.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
UBS
QuintilesIMS
Accenture
Cantor Fitzgerald
Julphar
Deloitte
Citi
Express Scripts
AstraZeneca

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022225

« Back to Dashboard
NDA 022225 describes BRIDION, which is a drug marketed by Organon Sub Merck and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the BRIDION profile page.

The generic ingredient in BRIDION is sugammadex sodium. One supplier is listed for this compound. Additional details are available on the sugammadex sodium profile page.

Summary for NDA: 022225

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1

Pharmacology for NDA: 022225

Ingredient-typegamma-Cyclodextrins

Suppliers and Packaging for NDA: 022225

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BRIDION
sugammadex sodium
 SOLUTION;INTRAVENOUS 022225 NDA Merck Sharp & Dohme Corp. 0006-5423 0006-5423-12 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-5423-12) > 2 mL in 1 VIAL, SINGLE-DOSE (0006-5423-02)
BRIDION
sugammadex sodium
 SOLUTION;INTRAVENOUS 022225 NDA Merck Sharp & Dohme Corp. 0006-5423 0006-5423-15 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-5423-15) > 5 mL in 1 VIAL, SINGLE-DOSE (0006-5423-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 500MG BASE/5ML (EQ 100MG BASE/ML)
Approval Date:Dec 15, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 15, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:RE44733Patent Expiration:Jan 27, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:REVERSAL OF DRUG-INDUCED NEUROMUSCLUAR BLOCK
Patent:6,949,527Patent Expiration:Jan 27, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:REVERSAL OF NEUROMUSCLUAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Chubb
Moodys
Novartis
Citi
Accenture
US Department of Justice
Federal Trade Commission
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot